Philip Storey1, Michael Dollin1, John Pitcher1, Sahitya Reddy2, Joseph Vojtko2, James Vander1, Jason Hsu1, Sunir J Garg3. 1. The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. 2. Department of Ophthalmology, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: sunirgarg@yahoo.com.
Abstract
OBJECTIVE: To compare the incidence of endophthalmitis after intravitreal injection with and without topical postinjection antibiotic prophylaxis. DESIGN: Retrospective case-control study. PARTICIPANTS: All patients treated with intravitreal injection of ranibizumab, bevacizumab, or aflibercept for a variety of retinal vascular diseases at a single, large retina practice between January 1, 2009, and October 1, 2012, were included. METHODS: The total numbers of patients and injections were determined from a review of billing code and practice management records. Endophthalmitis cases were determined from billing records and from an infection log. All cases of endophthalmitis were confirmed with chart review. A 28-month period when topical antibiotics were prescribed after intravitreal injection was compared with a 9-month period when topical antibiotics were not prescribed. Patients treated during an 8-month transition period were excluded to allow for the conversion of antibiotic prescription practices. MAIN OUTCOME MEASURES: Incidence of endophthalmitis, visual acuity outcomes, and microbial spectrum. RESULTS: During the study period, a total of 117 171 intravitreal injections were performed (57 654 injections during the topical antibiotic period, 24 617 during the transition period, and 34 900 during the no-antibiotic period), with a total of 44 cases of suspected endophthalmitis (0.038%; 1 in 2663 injections), 17 of which showed culture-positive results (0.015%; 1 in 6892 injections). During the 28-month topical antibiotic period, there were 28 cases of suspected endophthalmitis (0.049%; 1 in 2059 injections), 10 of which showed culture-positive results (0.017%; 1 in 5765 injections). During the 9-month no-antibiotic period, there were 11 cases of suspected endophthalmitis (0.032%; 1 in 3173 injections), 4 of which showed culture-positive results (0.011%; 1 in 8725 injections). Topical antibiotic use was associated with a trend toward increased risk of suspected endophthalmitis (odds ratio [OR], 1.54; 95% confidence interval [CI], 0.77-3.10) and culture-positive endophthalmitis (OR, 1.51; 95% CI, 0.47-4.83). CONCLUSIONS: The incidence of endophthalmitis after intravitreal injection is low. Using postinjection topical antibiotic drops does not reduce the risk of endophthalmitis developing and is associated with a trend toward higher incidence of endophthalmitis.
OBJECTIVE: To compare the incidence of endophthalmitis after intravitreal injection with and without topical postinjection antibiotic prophylaxis. DESIGN: Retrospective case-control study. PARTICIPANTS: All patients treated with intravitreal injection of ranibizumab, bevacizumab, or aflibercept for a variety of retinal vascular diseases at a single, large retina practice between January 1, 2009, and October 1, 2012, were included. METHODS: The total numbers of patients and injections were determined from a review of billing code and practice management records. Endophthalmitis cases were determined from billing records and from an infection log. All cases of endophthalmitis were confirmed with chart review. A 28-month period when topical antibiotics were prescribed after intravitreal injection was compared with a 9-month period when topical antibiotics were not prescribed. Patients treated during an 8-month transition period were excluded to allow for the conversion of antibiotic prescription practices. MAIN OUTCOME MEASURES: Incidence of endophthalmitis, visual acuity outcomes, and microbial spectrum. RESULTS: During the study period, a total of 117 171 intravitreal injections were performed (57 654 injections during the topical antibiotic period, 24 617 during the transition period, and 34 900 during the no-antibiotic period), with a total of 44 cases of suspected endophthalmitis (0.038%; 1 in 2663 injections), 17 of which showed culture-positive results (0.015%; 1 in 6892 injections). During the 28-month topical antibiotic period, there were 28 cases of suspected endophthalmitis (0.049%; 1 in 2059 injections), 10 of which showed culture-positive results (0.017%; 1 in 5765 injections). During the 9-month no-antibiotic period, there were 11 cases of suspected endophthalmitis (0.032%; 1 in 3173 injections), 4 of which showed culture-positive results (0.011%; 1 in 8725 injections). Topical antibiotic use was associated with a trend toward increased risk of suspected endophthalmitis (odds ratio [OR], 1.54; 95% confidence interval [CI], 0.77-3.10) and culture-positive endophthalmitis (OR, 1.51; 95% CI, 0.47-4.83). CONCLUSIONS: The incidence of endophthalmitis after intravitreal injection is low. Using postinjection topical antibiotic drops does not reduce the risk of endophthalmitis developing and is associated with a trend toward higher incidence of endophthalmitis.
Authors: Aaron Y Lee; Lakshmi Akileswaran; Michael D Tibbetts; Sunir J Garg; Russell N Van Gelder Journal: Ophthalmology Date: 2014-11-24 Impact factor: 12.079
Authors: Maxwell S Stem; Prethy Rao; Ivan J Lee; Maria A Woodward; Lisa J Faia; Jeremy D Wolfe; Antonio Capone; Douglas Covert; A Bawa Dass; Kimberly A Drenser; Bruce R Garretson; Tarek S Hassan; Alan Margherio; Kean T Oh; Paul V Raephaelian; Sandeep Randhawa; Scott Sneed; Michael T Trese; Sunita Yedavally; George A Williams; Alan J Ruby Journal: Ophthalmol Retina Date: 2018-09-25
Authors: Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2019-01-01 Impact factor: 1.300